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1. Introduction 
Natural polysaccharides are used in a variety of applications due to their unique properties. 
These applications range from paper manufacturing to wound healing [1]. One interesting class 
of polysaccharides comprises 1,3-β-glucans, which are glucopyranose polysaccharides with 
(1,3) glycosidic linkages and varying degree of (1,6) branches [2]. 1,3-β-glucans can form single 
or triple helical structures, which can be used to synthesize resilient gels by applying heat and 
humidity [3,4]. The properties of these gels are governed by the structure of the polysaccharide, 
which is determined by the degree of branching and the molecular weight. Thus, controlling the 
microscopic structure allows control over the macroscopic function. This is especially 
advantageous in the field of drug delivery because the encapsulation of different agents can be 
facilitated by the use of different polysaccharides. The properties of 1,3-β-glucans can also be 
modified by covalently attaching functional units to the polysaccharide backbone [5].  
1,3-β-glucans are derived from microbial [6] and fungal [2] sources and hence have innate 
immunomodulatory properties. When these 1,3-β-glucans are a component of the foreign 
pathogens, they can act as recognition sites for macrophages to facilitate the elimination and 
removal of these pathogens [7]. When extracted 1,3-β-glucans are administered to animals 
or humans, they recruit macrophages and stimulate the immune system through a similar 
mechanism [8,9]. This result has been utilized for various pharmacological applications 
including cancer inhibition [10-17], infection resistance [18-21] and wound healing [22-24]. 
Current research is focusing on combining the structural properties of 1,3-β-glucans with 
the pharmacological ones to further enhance the efficacy of hybrid systems thus created.  
2. Crystallinity of 1,3-β-glucans 
2.1. Structure 
1,3-β-glucans are semi-crystalline polysaccharides comprising a combination of single 
helices, triple helices and random coils. The crystallinity of these polysaccharides has been 
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studied using X-ray diffraction (XRD). In this study, curdlan, which is a linear 1,3-β-glucan, 
was used as a model polysaccharide [3]. Different forms and states of curdlan demonstrate 
different crystallinity. One example that was studied in detail is the annealed “dry” state, 
where the curdlan is dissolved in dimethyl sufoxide, extracted in methanol and annealed in 
the presence of water at 145 °C. Curdlan is then dried in vacuo to obtain the sample for XRD 
experiments. The results from XRD measurements conclude that six-fold triple-helices are 
formed with an advance of 2.935 Å per monomer unit.  The model of this structure confirms 
that the three strands of triple helices are held together by hydrogen bonding between O(2) 
hydroxyls while the helices are brought together by O(4) and O(6) hydrogen bonding [3]. 
An alternate structure of curdlan helices is presented based on semi-empirical modeling. It 
is proposed that hydrogen bonding of the strands occurs along the helix axis rather than 
perpendicular to it. The different structures are illustrated in Figure 1. It is demonstrated 
that this alternate structure provides a more stable structure of curdlan and hence is likely to 
have higher population [25].  
 
Figure 1. Illustration of possible orientations of curdlan triple helices: a) hydrogen bonding 
perpendicular to helix axis; b) hydrogen bonding along helix axis. Figure adapted from [25]. 
1,3-β-glucans have also been complexed with nucleotides to form crystalline structures. In 
the example of curdlan and poly(cytidylic acid) complex, semi-empirical modeling suggests 
that two glucose units of different curdlan chains form hydrogen bonds with one base of the 
nucleotide chain [26]. This property of curdlan complexing with nucleotides has been 
exploited in forming liquid crystalline gels with deoxyribonucleic acid (DNA). Such 
structures could be synthesized at varying scales ranging from nanometers to centimeters 
[27].  
2.2. Liquid crystalline gels 
Curdlan can be used to form liquid crystalline gels when it is exposed to transition metal salts 
[28,29]. The crystallinity of these gels depends on the molecular weight of the gels [30]. DNA 
has also been used to synthesize gel beads [31]. When used together, DNA and curdlan 
 
1,3--Glucans: Drug Delivery and Pharmacology 557 
provide control over the size and morphology of the synthesized hybrid structures. Various 
structures can be obtained by modifying the concentration of curdlan and DNA [27].  
Curdlan is insoluble in water but it dissolves in alkaline solutions. Thus, DNA and curdlan 
are mixed together in a basic solution and then this mixture is added to a solution of calcium 
chloride salt either directly or through a dialysis membrane. Direct addition leads to 
formation of structures at the nanometer and millimeter scales. Dialysis allows for the 
formation of centimeter sized gels. The macroscopic structures are assessed by using crossed 
nicols (Figure 2), while the nano- and micro-structures are characterized using transmission 
electron microscopy (TEM, Figure 4). When viewing the centimeter scale gels between two 
perpendicularly placed polarizers, orthogonal dark lines are observed on the gels. These 
lines are known as isogyres and indicate the anisotropy in liquid crystalline gels. It is 
observed that increasing the concentration of DNA decreases the crystallinity of the gel as 
the isogyres become less defined. This is illustrated in Figure 2 [27]. 
 
Figure 2. Liquid crystalline gels of curdlan and DNA: 100% curdlan, 5% DNA, 10% DNA and 20 % 
DNA as seen under visible light (top) and crossed nicols (bottom). Scale bars are 1 cm each. Figure 
obtained from [27]. 
A similar phenomenon was observed at the milimeter scale when the structure was 
observed under the microscope. It was seen that although DNA provided rigidity and well-
defined shape to the structure, it reduced the crystallinity. This is likely because DNA forms 
a less crystalline structure compared to curdlan. It is possible that DNA might not be 
forming helices with curdlan, but instead forming a gel with microphase separation. The 
results from millimetre scale are highlighted in Figure 3. The opacity and lack of isogyres in 
DNA sample implies low crystallinity. Thus, a simple method is presented to determine 
degree of crystallinity of gels qualitatively [27]. 
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Figure 3. Spherical gels of curdlan and DNA observed under visible light (top and middle) and 
polarized light (bottom). Scale bars are 1 mm each. Figures obtained from [27]. 
 
Figure 4. TEM images of micro- and nano-structures of curdlan and DNA. White scale bars are 500 nm 
and black scale bars are 2000 nm. Figure reproduced from [27]. 
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At the micro- and nano-scale levels, the morphology of the gels could be changed between 
spheres and fibers by modulating the concentration of the DNA or curdlan. This is 
summarized in Figure 4. These hybrid liquid crystalline gel systems have the potential of 
creating advanced drug delivery vehicles where the crystalline regions of the system 
prevent degradation of the biomolecule and the amorphous regions maintain 
functionality of the encapsulated moiety. This hybrid system also serves as a tool for 
further studies of the molecular structure undertaken by 1,3-β-glucan and DNA in various 
microenvironments [27].  
3. Applications in drug delivery 
The ability to control the structure of 1,3-β-glucan based carriers has encouraged the 
application of these glucans in drug delivery. The glucans can be used as gels, nanoparticles, 
microparticles or complexes.  
3.1. Encapsulation within gels 
Curdlan is the commonly used 1,3-β-glucan for formation of gels. Curdlan gels can be 
prepared by heating the suspension of curdlan in aqueous solution and then cooling it 
down. If the suspension is heated to 60 °C, a low-set thermally reversible gel is formed 
whereas if the temperature is above 80 °C, a high-set thermally irreversible gel is formed. 
Drugs such as indomethacin, salbutamol sulfate and prednisolone have been 
encapsulated in curdlan gels. The gels are prepared by mixing curdlan in drug solutions 
at 5-10% curdlan concentration, adding the suspension to a glass test tube, heating the test 
tube in water bath at the desired temperature for 10 minutes and then unmolding the gel. 
The experiments conducted in [32] have demonstrated that a high-set gel can lower the 
rate of drug release. The curdlan based gels have been able to provide a sustained release 
of drugs for compared to commercially available formulations. These gels can be used as 
drug delivery suppositories for rectal administration, which bypasses hepatic first pass 
clearance [32].  
Curdlan gels have also been used for developing protein delivery devices. Since proteins 
can denature at high temperatures, the temperature required for forming curdlan gels 
needs to be lowered. Curdlan can form aqueous gels in the presence of hydrogen bond 
disrupting agents such as dimethyl sulfoxide, urea and thiocyanates [33]. This property 
encourages the use of chaotropes for lowering the gelling temperature. It has been 
demonstrated that the presence of 8 M urea can decrease the gelling temperature of 
curdlan from 55 °C to 37 °C. This has been used for encapsulating bovine serum albumin 
(BSA) as a model protein. Although gels synthesized using urea are able to demonstrate 
sustained release of BSA over 100 hours, the toxicity of urea is a concern. Urea also has the 
possibility of disrupting the hydrogen bonds of BSA and hence denaturing the protein. 
Thus, an alternative method of reducing the gelling temperature has been developed by 
modifying the backbone of curdlan to form a hydroxyethyl derivative. This system was 
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also able to form gels at 37 °C but the BSA release was sustained for a shorter time period 
of 75 hours [34].  
3.2. Microparticles and nanoparticles 
Nanoparticles are typically used in drug delivery applications because of high drug 
encapsulation efficiency [35], controlled drug release and incorporation of diagnostic 
agents [36,37]. One of the major challenges with drug delivery is achieving specificity 
with cellular uptake. One method of overcoming this hurdle is by attaching targeting 
ligands on the surface of nanoparticles to allow enhanced uptake by specific cells [38]. 
Another strategy is the encapsulation of these drug loaded nanoparticle in glucan based 
microspheres. Glucan microspheres are derived from the cell walls of Sacchamoryces 
cerevisiae (Baker’s yeast) and are 2-4 µm in size. These are porous and hollow 
microparticles composed mainly of 1,3-β-D-glucan and small quantities of chitin [39]. The 
β-glucan on the microspheres serves as a specific target for uptake by immune cells such 
as macrophages and dendritic cells [40]. Glucan microspheres can be used for delivering 
various payloads such as proteins [19], DNA [40], siRNA [16,41] and small molecules [39]. 
Typically small molecules are not easily entrapped within these glucan microspheres and 
hence the use of nanoparticles is necessary. These nanoparticles can then be loaded in 
glucan microspheres for enhanced uptake. Recently, two types of nanoparticles have been 
encapsulated within glucan microspheres: fluorescent polystyrene nanoparticles and 
doxorubicin loaded mesoporous silica nanoparticles [39]. The polystyrene particles are 
encapsulated using capillary forces from the pores of microspheres, whereas the silica 
nanoparticles are loaded using electrostatic interactions. These particles are then used in 
vitro to demonstrate enhanced uptake by dectin-1 expressing fibroblast cells (NIH3T3-D1 
cell line). It has been observed that doxorubicin loaded silica nanoparticles were more 
effective when encapsulated within glucan microspheres because of enhanced uptake. 
These results were consistent with fluorescently tagged polystyrene nanoparticle uptake 
as well [39].  
Aside from being used as a targeting moiety, 1,3-β-glucans have also been used as structural 
units for encapsulating insoluble drugs. One example is the use of short chain curdlan with 
a molecular weight of 990 Da, derived from Vietnam medicinal mushroom Hericium 
erinaceum. This curdlan has been used to synthesize a nanoparticle formulation for 
encapsulating curcumin, which is a water-insoluble compound with promising anti-cancer 
activity. Curcumin is derived from the rhizomes of the herb Curcuma longa and has 
demonstrated cancer prevention and suppression through various signaling pathways [42]. 
The delivery of curcumin has been enhanced by encapsulating it within curdlan to form 50 
nm nanoparticles. These nanoparticles are prepared by adding curcumin dissolved in 
ethanol to a solution of curdlan in water and stirring at room temperature. The solvents are 
then evaporated and nanoparticles are purified by centrifugation to remove excess curdlan 
and larger aggregates. These curcumin loaded curdlan nanoparticles have been able to 
inhibit tumor growth in Hep-G2 cell line in vitro [10]. 
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Amphiphilic derivatives of 1,3-β-glucans have also been extensively studied for formation 
of micellar nanoparticles with drug encapsulating capabilities. One example of an 
amphiphilic system is based on cholesterol-carboxymethylcurdlan. The hydrophilicity of 
curdlan is increased by modifying the backbone with carboxymethyl groups. The loading of 
hydrophobic drugs is increased by inclusion of cholesterol moieties in the curdlan backbone 
[17]. This system uses a remote loading method for encapsulating epirubicin, where a pH 
gradient between the interior and exterior of the nanoparticle is utilized to achieve high 
ratio of drug to carrier [43]. Remote loading method is implemented by preparing blank 
cholesterol-carboxymethylcurdlan nanoparticles using probe sonication, resuspending dried 
nanoparticles in ammonium sulfate, performing buffer exchange in sodium chloride and 
finally adding the desired amount of epirubicin to the solution. This method is able to 
achieve up to 39.6% drug loading, which is remarkable for polymeric systems. This curdlan 
based delivery device has been able to enhance the cytotoxicity of epirubicin in vitro when 
assessed using human cervical carcinoma (HeLa) cell lines as compared to free epirubicin. 
The delivery vehicle also increases the circulation half-life in vivo by 4.31 times as compared 
to free epirubicin when tested in Wistar rats. These results provide promising opportunities 
for utilizing a curdlan based drug delivery vehicle for enhanced efficacy of encapsulated 
drugs.  
Alternatively, curdlan can also be used as the hydrophobic component in an amphiphilic 
drug delivery vehicle. To achieve this a graft copolymer of curdlan and poly(ethylene 
glycol) (PEG) has been synthesized [5]. PEG is a commonly used polymer for enhanced 
biocompatibility [44-48]. Doxorubicin can be incorporated in graft copolymer nanoparticle 
by nanoprecipitation method. In this technique, the copolymer and drug are dissolved in a 
common water miscible solvent and then added to magnetically stirred water in a drop-wise 
manner. The mixing causes self-assembly of polymers where hydrophobic components are 
at the core of the nanoparticle and hydrophilic components are at the surface. In the case of 
doxorubicin and curdlan-graft-PEG, dimethyl sulfoxide is used as the common solvent [5]. 
A schematic of the nanoparticle is presented in Figure 5.  
The structure of curdlan-graft-PEG nanoparticles has been confirmed using TEM. The 
samples were stained using phosphotungstic acid, which acts as a negative stain. This 
makes the background appear dark and the samples of interest appear bright. Additionally, 
since phosophotungstic acid is hydrophilic, hydrophobic components will be excluded from 
the acid and hence appear brighter than hydrophilic components. As observed in Figure 6, 
the nanoparticles are about 109 nm in size. Doxorubicin is visible as the bright center of the 
nanoparticles. Figure 6 (B) shows the three distinct layers of the nanoparticle, which 
correspond well with the schematic presented in Figure 5 [5].  
The doxorubicin formulation with curdlan-graft-PEG was tested in vitro to determine its 
drug release profile and it demonstrated sustained release over 24 hours following a Fickian 
diffusion release model. Since PEG graft is supposed to improve the biocompatibility of the 
nanoparticles, a hemolysis assay was implemented to assess this property. Sheep red blood 
cells (RBCs) were used for this assay and nanoparticles of interest were incubated with the 
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RBCs for one hour at 37 °C. The amount of lysis was compared to a negative control of 
veronal buffered saline and positive control of deionized water. Curdlan-graft-PEG 
nanoparticles showed hemolysis below 5% at clinically relevant concentrations [5], which is 
considered biocompatible [35].  
 
Figure 5. Schematic of nanoparticle synthesized using curdlan-graft-poly(ethylene glycol) and 
doxorubicin. Doxorubicin is at the core, surrounded by curdlan and PEG forms the shell. Figure 
adapted from [5]. 
 
Figure 6. TEM images of doxorubicin encapsulated within curdlan-graft-PEG nanoparticles.  
(A) Bright center indicates doxorubicin and surroundings are darker because of higher electron density; 
(B) Three layers of the nanoparticle can be seen: bright doxorubicin core, dense curdlan layer in the 
middle and sparse PEG layer on the shell. Scale bars are 200 nm. Figure adapted from [5]. 
Therefore, nanoparticles and microparticles based on 1,3-β-glucans provide promising 
opportunities for drug delivery as structural units and as targeting ligands. The combination 
of these properties can be exploited for developing a drug delivery vehicle with enhanced 
potency.  
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3.3. Glucan complexes with polynucleotides 
Polynucleotides have found several applications in drug delivery as active agents due to their 
therapeutic effects [16,41,49]. One of the challenges faced by polynucleotide delivery is their 
rapid degradation in vivo. Encapsulation of polynucleotides thus becomes necessary for 
maintaining their function. 1,3-β-glucans are a preferred choice for forming these complexes 
because of their helix forming capabilities. In the past, several polysaccharides have been 
tested for their ability to form complexes with the polynucleotide poly(C) and the 
complexation was assessed using circular dichorism (CD) where a change in the spectrum 
indicates complex formation. Only schizophyllan (1,3-β-glucan with one 1,6 branch every 
three units) and lentinan (1,3-β-glucan with two 1,6 branch every five units) have 
demonstrated changes in CD spectra, whereas curdlan, amylose (1,4-α-glucan), dextran (1,6-α-
glucan) and pullulan (1,4-α-1,6-α-glucan) did not show any changes. This implies that only 
soluble 1,3-β-glucans are able to form complexes with poly(C). Commercially available 
curdlan is unable to form a complex because of its low solubility in water, which leads to 
precipitation [50]. The solubility of curdlan can be improved by reducing the molecular weight 
of the polymer. At lower molecular weight, curdlan is able to form complexes with poly(C) but 
these complexes are not as stable as the ones formed with schizophyllan [51]. Complexes have 
also been formed with poly(A) using schizophyllan but poly(U) showed no complexation, 
which suggests that polysaccharides can bind to polynucleotides in a specific manner [52]. 
Curdlan backbone has also been modified with carbohydrate molecules using click chemistry 
to improve the solubility and hence induce complex formation with poly(C) [53].  
Hitherto, only homo-sequence polynucleotides have been discussed. Often therapeutic 
polynucleotides are composed of heterogeneous base pairs. Drug delivery vehicles for 
hetero-sequence oligonucleotides have also been developed by synthesizing cationic curdlan 
chains. CpG DNA has demonstrated immune stimulating effects but it needs to be 
preserved from degradation [54]. Cationic curdlan, synthesized using click chemistry, has 
been able to form complexes with CpG DNA and increase the cellular uptake in 
macrophage-like cell line J774.A1. The complex also induces an increase in cytokine (IL-12) 
secretion, which suggests activation of the macrophage cells [54]. Another strategy of 
binding hetero-sequence oligonucleotides is by modification of one terminal to attach a 
homo-sequence such as poly(A). A schizophyllan derivative has been utilized for binding 
modified antisense oligonucleotides. Schizophyllan has been modified with galactose and 
PEG units to enhance cellular uptake. It has been observed that the antisense effect was 
maximized with the use of schizophyllan derivative when the complex is administered to 
hepatoblastoma HepG2 and melanoma A375 cell lines [55]. Thus, 1,3-β-glucan based drug 
delivery devices serve as biocompatible carriers for a variety of nucleotides.  
4. Applications in immunotherapy 
1,3-β-glucans have been known to generate an immune response including stimulation of 
cytokine production, oxidative burst, increased phagocyte and lymphocyte proliferation as 
well as phagocytosis of opsonized tissues. Various mechanisms are responsible for this 
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activation and this response has been utilized for varied applications including cancer 
resistance, disease immunity and wound healing [56].  
4.1. Biological pathways of activation 
The complement system is responsible for innate immunity and can be activated by either 
classical, alternative or lectin pathways. Using lentinan, pachyman and pachymaran 
polysaccharides, it has been demonstrated that 1,3-β-glucans use the alternative pathway of 
complement activation for generating an immune response since they show an increased 
consumption of C3 and C5 proteins from the complement cascade [57]. Additionally, 
opsonization is an important component of innate immune response. Typically complement 
protein C3b gets coated on pathogens and is later detected by complement receptor 1 or 
deactivated to form iC3b for regulation. In the presence of 1,3-β-glucans, iC3b can be 
detected by complement receptor 3 (CR3) or dectin-1 and this mechanism can be exploited 
for attacking cancer cells coated with iC3b [8]. Although the effect of CR3 has been 
negligible in immune activation in murine models [9,58], functional CR3 is essential for 
phagocytosis in human neutrophils [59].  
Most of the existing studies have focused on macrophages and neutrophils but some 1,3-β-
glucans such as lentinan are responsible for stimulation of T-cells and natural killer cells and 
hence affect the acquired immune response [60,61]. Curdlan has also been used to demonstrate 
increased proliferation of lymphocytes, which can in turn enhance the immune response [62]. 
Oxidative burst is yet another immunomodulatory effect that has been demonstrated by 1,3-β-
glucans. While curdlan has shown the induction of inducible nitric oxide synthase in rat 
macrophages [63], other 1,3-β-glucans have shown an increase in the production of reactive 
oxygen species [62]. Some studies have demonstrated that immune activation is only possible 
by linear 1,3-β-glucans [64] while others emphasize that complex branching is important for 
most effective stimulation of immune response [65]. Although, several aspects of the biological 
pathways of activation have been discovered, further studies are necessary to gain a better 
understanding of the intricate interactions between 1,3-β-glucans and the immune system.  
4.2. Tumor suppression 
The use of 1,3-β-glucans in cancer therapy has been present in Japan since 1986, where they 
have been used for gastric, lung and cervical cancers [66]. Lentinan and pachymaran have 
demonstrated high tumor inhibition ratios of 99.6% and 96%, when tested against 
subcutaneous implantation of sarcoma 180 in mice [64]. It is hypothesized that the effect of 
lentinan and pachymaran is highly dependent on the activation of T-lymphocytes because the 
removal of the thymus from mice caused a suppression of antitumor effects from the 1,3-β-
glucans [60]. Additionally, it is also speculated that deactivation of protein helices might be 
important for antitumor effects because a study has demonstrated that only polysaccharides 
that deactivated bovine serum albumin showed antitumor activity [67]. Besides lentinan and 
pachymaran, other 1,3-β-glucans have also exemplified tumor suppression. Some of the 
prominent examples are scleroglucan with an inhibition ratio of 90.4%, curdlan with inhibition 
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of 99-100% [68], grifolan with inhibition of 97.9% [69] and 1,3-β-glucan from Agaricus blazei 
with inhibition of 99.3% [65]. These results have been encouraging and hence 1,3-β-glucans 
have been used in combinatorial therapies with antibodies in implanted human tumor 
xenografts from melanoma, epidermoid carcinoma, breast carcinoma, metastatic lymphoma 
and daudi lymphoma. The mice had higher survival rates in the presence of 1,3-β-glucans as 
compared to treatment with antibodies alone [12].  
Subsequently, water soluble 1,3-β-glucans have been derived to improve the usability of 
these polysaccharides. Some examples of these polysaccharides include 
carboxymethylpachymaran with tumor inhibition ratio of 99.6%, 
hydroxymethylpachymaran and hydroxypropylpachymaran with up to 100% tumor 
inhibition when assessed against solid sarcoma 180 at a dose of 5 mg/kg [70]. Several 
derivatives of curdlan including carboxymethyl, glucosyl, sulfoethyl and sulfopropyl 
attachments to the backbone have also retained antitumor activity [71,72]. These examples 
demonstrate the versatility of 1,3-β-glucans in cancer inhibition and thus these 
polysaccharides can be modified to suit the desired application. 
4.3. Infection prevention 
Most common infections are caused by bacteria and fungi and since 1,3-β-glucans can induce 
inflammatory response, these glucans can be used for providing infection resistance. It has 
been shown that when administering 1,3-β-glucan to mice, their survival against Staphylococcus 
aureus infection increased from 70% to 97% [73]. Other 1,3-β-glucans such as glucan phosphate, 
laminarin and scleroglucan have been studied in detail for assessing their pharmacokinetic 
profile following oral administration in rats. It has been observed that these glucans are able to 
translocate from the gastrointestinal tract to systemic circulation. The glucans were able to 
increase secretion of interleukins, increase expression of dectin-1 on macrophages and increase 
expression of toll-like receptor 2 on dendritic cells. Thus, these effects increase the long-term 
survival of rats from 0% to 40% when challenged with Candida albicans fungal infection and 
from 0% to 50% when challenged with Staphyloccous aureus bacterial infection [74].  
When considering larger mammals, infection resistance in pigs, dogs and horses has also 
found applications of 1,3-β-glucans. When piglets were fed with β-glucans after weaning, 
they demonstrated lower infection from enterotoxigenic Escherichia coli, which was 
highlighted by decreased diarrhoea and decreased content of inoculated Escherichia coli in 
the faeces as compared to control groups. These results present a significant advancement in 
veterinary medicine for pigs because the immunity of pigs usually suffers severely right 
after weaning and the current vaccines against Escherichia coli take a long period to be 
effective [20]. In the case of horses, the administration of 1,3-β-glucan to pregnant mares has 
been able to increase the cellular immune response in foals. This becomes very useful for 
preventing premature deaths of neonates [75]. While most studies have focused on the 
effects of 1,3-β-glucans on improving innate immunity, when these polysaccharides are 
administered to dogs, they showed enhancement in humoral immunity as indicated by 
changes in serum IgM and IgA levels [18].  
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1,3-β-glucans have also been used in aquatic animals as exemplified by the use of schizophyllan 
with 60-80% survival rate and lentinan and scleroglucan with 55-75% survival rate when tested 
against Edwardsiella tarda bacteria attack on Cyrinus carpio L. carp. The survival rate was also 
increased when infected with Aeromonas hydrophila with survival of 60% with schizophyllan, 
70% with lentinan and 80% with scleroglucan administration. In the absence of glucans, the 
carp underwent complete mortality upon any infection [76]. These results have been repeatable 
when tilapia and grass carp is exposed to Aeromonas hydrophila [77]. As more studies are 
conducted on the use of 1,3-β-glucans, the quality of veterinary health care can be improved  
further and these results can eventually be transferred to human applications. 
In addition to bacterial and fungal resistance, 1,3-β-glucans have also demonstrated 
promising results against malaria [78], herpes simplex virus [79] and human 
immunodeficiency virus (HIV) [80-82]. Expanding on HIV research, various complexes have 
been synthesized with curdlan sulfate in order to enhance the efficacy of the polysaccharide. 
Some prominent examples include covalent conjugation of azidothymidine to curdlan 
sulfate for drug delivery to the lymph nodes and bone marrow [83] and conjugation of 
fullerene C60 with curdlan for combining their anti-HIV effects [84]. 
4.4. Wound healing 
1,3-β-glucans can have an impact on wound healing by recruiting macrophages to the 
wound site [85] and by increasing collagen deposition [24]. Beta glucan collagen matrix 
wound dressings have been used in children suffering from partial thickness burns and 
the dressings were able to simplify wound care by reducing analgesic requirements, 
improving cosmetic results and eliminating the need for repetitive dressing changes [86]. 
Other composites of β-glucan have been created with poly(vinyl alcohol) [23] and 
chitosan [22]. Poly(vinyl alcohol)/β-glucan composite was able to speed up the wound 
healing process when tested using rat models and hence decreased the healing time by 
48% as compared to cotton gauze [23]. When using a composite of β-glucan and chitosan, 
a transparent dressing was obtained, which showed better results compared to 
commercially available chitosan based Beschitin® W. The synthesized chitosan composite 
did not dissolve during application period and was easy to remove because it did not 
adhere to wounds [22].  
5. Conclusion 
An assortment of 1,3-β-glucans have been explored for their structural and pharmacological 
capabilities. The ability of 1,3-β-glucans to form helical structures and gels has been 
advantageous for forming complexes with small molecules and macromolecules. The 
immunomodulatory effects of 1,3-β-glucans have served to fight cancer and infections and 
to promote wound healing.  Research is moving towards combining the ability of 1,3-β-
glucans to encapsulate bioactive agents with their own bioactivity for creating potent 
therapeutic devices against current challenges.  
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